{"id":21680,"date":"2023-12-20T08:23:47","date_gmt":"2023-12-20T07:23:47","guid":{"rendered":"https:\/\/ggba.swiss\/?p=21680"},"modified":"2023-12-20T08:23:48","modified_gmt":"2023-12-20T07:23:48","slug":"gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/","title":{"rendered":"GliaPharm receives USD 4.2 million to propel Alzheimer\u2019s treatment development"},"content":{"rendered":"\n

Founded in 2017, GliaPharm<\/a> specializes in developing treatments for neurological diseases by focusing on glial cell function. Their in-house drug discovery platform, GliaX<\/a>, has produced a pipeline of compounds designed to improve brain energy metabolism, a critical factor in neurodegenerative diseases.<\/p>\n\n\n\n

Alzheimer\u2019s disease, characterized by reduced glucose uptake in the brain or hypometabolism, currently lacks specific treatments to address this metabolic decline. GliaPharm\u2019s lead candidate, GP-119, is an orally active small molecule targeting this issue. The USD 4.2 million investment will support the progression of GP-119 through Investigational New Drug (IND)\/Clinical Trial Application (CTA)-enabling studies, essential for gaining approval for clinical testing by regulatory agencies like the FDA in the US and the EMA in Europe.<\/p>\n\n\n\n

Dr. Howard Fillit, Co-Founder and Chief Science Officer at the ADDF<\/a>, has highlighted the significance of this development: \u201cDeveloping new drugs that regulate brain metabolism in ageing bodies, like GliaPharm\u2019s GP-119, is a promising approach for treating Alzheimer\u2019s and related dementias. We hope to develop an arsenal of drugs that can stop the disease in its tracks through combination therapy and precision medicine.\u201d<\/p>\n\n\n\n

Ambroise Magistretti, Co-CEO and Co-Founder of GliaPharm, expressed gratitude for the ADDF’s investment, recognizing it as a strong endorsement of their Alzheimer\u2019s program. Dr. Charles Finsterwald, GliaPharm\u2019s CSO and Co-Founder, added that the ADDF\u2019s support is crucial for advancing their lead program through preclinical regulatory studies, setting the stage for subsequent clinical trials. He also noted the ADDF\u2019s strategy to support novel and potentially complementary therapeutic solutions for Alzheimer\u2019s disease, including GliaPharm\u2019s approach to tackle brain hypometabolism.<\/p>\n","protected":false},"excerpt":{"rendered":"

GliaPharm, an innovative EPFL spin-off, has secured a USD 4.2 million investment from the Alzheimer\u2019s Drug Discovery Foundation (ADDF) to advance its leading Alzheimer\u2019s disease treatment through crucial preclinical studies.<\/p>\n","protected":false},"author":6,"featured_media":21681,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,894,890,902,911,886],"class_list":["post-21680","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-financing","tag-healthcare","tag-personalized-medicine","tag-pharma","tag-rd"],"acf":[],"yoast_head":"\nGliaPharm receives USD 4.2M to advance Alzheimer\u2019s treatment<\/title>\n<meta name=\"description\" content=\"GliaPharm has secured a USD 4.2M investment from Alzheimer\u2019s Drug Discovery Foundation (ADDF) to advance its Alzheimer\u2019s disease treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GliaPharm receives USD 4.2M to advance Alzheimer\u2019s treatment\" \/>\n<meta property=\"og:description\" content=\"GliaPharm has secured a USD 4.2M investment from Alzheimer\u2019s Drug Discovery Foundation (ADDF) to advance its Alzheimer\u2019s disease treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-20T07:23:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-20T07:23:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/GliaPharm_2360x1622-1024x704.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"704\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"GliaPharm receives USD 4.2 million to propel Alzheimer\u2019s treatment development\",\"datePublished\":\"2023-12-20T07:23:47+00:00\",\"dateModified\":\"2023-12-20T07:23:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/\"},\"wordCount\":277,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/GliaPharm_2360x1622.jpeg\",\"keywords\":[\"Biotech\",\"Financing\",\"Healthcare\",\"Personalized Medicine\",\"Pharma\",\"R&D\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/\",\"url\":\"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/\",\"name\":\"GliaPharm receives USD 4.2M to advance Alzheimer\u2019s treatment\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/GliaPharm_2360x1622.jpeg\",\"datePublished\":\"2023-12-20T07:23:47+00:00\",\"dateModified\":\"2023-12-20T07:23:48+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"GliaPharm has secured a USD 4.2M investment from Alzheimer\u2019s Drug Discovery Foundation (ADDF) to advance its Alzheimer\u2019s disease treatment.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/GliaPharm_2360x1622.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/GliaPharm_2360x1622.jpeg\",\"width\":2360,\"height\":1622,\"caption\":\"This funding and partnership with the ADDF place GliaPharm at the forefront of developing effective treatments for Alzheimer\u2019s, offering new hope in the fight against this challenging neurodegenerative disease.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GliaPharm receives USD 4.2 million to propel Alzheimer\u2019s treatment development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GliaPharm receives USD 4.2M to advance Alzheimer\u2019s treatment","description":"GliaPharm has secured a USD 4.2M investment from Alzheimer\u2019s Drug Discovery Foundation (ADDF) to advance its Alzheimer\u2019s disease treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/","og_locale":"en_US","og_type":"article","og_title":"GliaPharm receives USD 4.2M to advance Alzheimer\u2019s treatment","og_description":"GliaPharm has secured a USD 4.2M investment from Alzheimer\u2019s Drug Discovery Foundation (ADDF) to advance its Alzheimer\u2019s disease treatment.","og_url":"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2023-12-20T07:23:47+00:00","article_modified_time":"2023-12-20T07:23:48+00:00","og_image":[{"width":1024,"height":704,"url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/GliaPharm_2360x1622-1024x704.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"GliaPharm receives USD 4.2 million to propel Alzheimer\u2019s treatment development","datePublished":"2023-12-20T07:23:47+00:00","dateModified":"2023-12-20T07:23:48+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/"},"wordCount":277,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/GliaPharm_2360x1622.jpeg","keywords":["Biotech","Financing","Healthcare","Personalized Medicine","Pharma","R&D"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/","url":"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/","name":"GliaPharm receives USD 4.2M to advance Alzheimer\u2019s treatment","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/GliaPharm_2360x1622.jpeg","datePublished":"2023-12-20T07:23:47+00:00","dateModified":"2023-12-20T07:23:48+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"GliaPharm has secured a USD 4.2M investment from Alzheimer\u2019s Drug Discovery Foundation (ADDF) to advance its Alzheimer\u2019s disease treatment.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/GliaPharm_2360x1622.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/12\/GliaPharm_2360x1622.jpeg","width":2360,"height":1622,"caption":"This funding and partnership with the ADDF place GliaPharm at the forefront of developing effective treatments for Alzheimer\u2019s, offering new hope in the fight against this challenging neurodegenerative disease."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/gliapharm-receives-usd-4-2-million-to-propel-alzheimers-treatment-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"GliaPharm receives USD 4.2 million to propel Alzheimer\u2019s treatment development"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/21680","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=21680"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/21680\/revisions"}],"predecessor-version":[{"id":21684,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/21680\/revisions\/21684"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/21681"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=21680"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=21680"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=21680"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}